M6P Therapeutics

Executive Summary

M6P Therapeutics (M6PT) is a privately held biotechnology company advancing next-generation enzyme replacement and gene therapies for lysosomal storage disorders (LSDs). Founded in 2018 and based in St. Louis, Missouri, the company's core innovation is a proprietary platform that enhances the targeting of therapeutic enzymes to lysosomes by optimizing mannose-6-phosphate (M6P) receptor binding. This approach aims to improve cellular uptake and biodistribution, addressing key limitations of current enzyme replacement therapies, such as inadequate tissue penetration and suboptimal efficacy. M6PT's platform has the potential to be applied across multiple LSDs, including Gaucher disease, Fabry disease, and Pompe disease, among others. While the company remains in early preclinical stages, its technology represents a differentiated strategy to overcome longstanding challenges in LSD treatment. With a focus on precision delivery, M6PT could enable lower dosing, reduced immunogenicity, and better patient outcomes. The company's progress, however, is contingent on successful preclinical validation and securing regulatory milestones to advance toward clinical trials.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Program60% success
• Q3 2026Preclinical Proof-of-Concept Data Presentation80% success
• Q2 2027Strategic Partnership or Licensing Deal50% success